Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties

American Journal of Transplantation

Volumn 5, Issue 3, 2005, Pages 443-453

  Larsen, Christian P ^a   Pearson, Thomas C ^a   Adams, Andrew B ^a   Tso, Paul ^a   Shirasugi, Nozomu ^a   Strobert, Elizabeth ^a   Anderson, Dan ^a   Cowan, Shannon ^a   Price, Karen ^b   Naemura, Joseph ^b   Emswiler, John ^b   Greene, JoAnne ^b   Turk, Lori Ann ^b   Bajorath, Jurgen ^b   Townsend, Robert ^b   Hagerty, David ^b   Linsley, Peter S ^b   Peach, Robert J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

CD28; Co stimulation; CTLA4 Ig; Non human primate; Transplantation

Indexed keywords

ALANINE; B7 ANTIGEN; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUTAMIC ACID; IMMUNOSUPPRESSIVE AGENT; LEUCINE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; NONHUMAN; ORGAN TRANSPLANTATION; PRIMATE; PRIORITY JOURNAL; RODENT; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IMMUNOCONJUGATES; KINETICS; MEMBRANE GLYCOPROTEINS; PROTEIN ENGINEERING; T-LYMPHOCYTES;

EID: 20044386299     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00749.x     Document Type: Article

References (27)

1. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994; 6: 414-419.
2. Anderson DE, Sharpe AH, Hafler DA. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol 1999; 11: 677-683.
3. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
4. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
5. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988.
6. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
7. Lenschow DJ, Ho SC, Sattar H et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145-1155.
8. Lenschow DJ, Zeng Y, Hathcock KS et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 1995; 60: 1171-1178.
9. Pearson TC, Alexander DZ, Corbascio M et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997; 63: 1463-1469.
10. Kirk AD, Tadaki DK, Celniker A et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72: 377-384.
11. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915.
12. Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187-5191.
13. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94: 8789-8794.
14. Greene JL, Leytze GM, Emswiler J et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 1996; 271: 26762-26771.
15. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1: 793-801.
16. Ronchese F, Hausmann B, Hubele S, Lane P. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo. J Exp Med 1994; 179: 809-817.
17. Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869-1874.
18. Khoury SJ, Akalin E, Chandraker A et al. CD28-B7 costimulatory blockade by CTLA4-lg prevents actively induced experiemental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155: 4521-4524.
19. Griggs ND, Agersborg SS, Noelle RJ, Ledbetter JA, Linsley PS, Tung KS. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J Exp Med 1996; 183: 801-810.
20. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997; 185: 393-403.
21. Peach RJ, Bajorath J, Brady W et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994; 180: 2049-2058.
22. Agrawal S, Agrawal A, Doughty B et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol 2003; 171: 4984-4989.
23. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
24. Bostom AD, Brown RS, Jr., Chavers BM et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500.
25. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
26. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
27. Linsley PS, Greene JL, Tan P et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176: 1595-1604.